Trials / Terminated
TerminatedNCT04819386
NEIVATECH Virtual Reality-based System for Amblyopia
Prospective Pilot Study of the NEIVATECH Virtual Reality-based System to Improve Visual Function in Children with Amblyopia
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Increase-Tech · Academic / Other
- Sex
- All
- Age
- 7 Years – 15 Years
- Healthy volunteers
- Not accepted
Summary
The NEIVATECH system has been designed to provide binocular vision training to 7-15 year old amblyopic children by discriminating Gabor patches presented with different contrast to each eye as a perceptual learning task.
Detailed description
Due to the global impact of amblyopia, there is a medical and social need, and at the same time, a clear market niche, for the design and development of new therapies that can improve recurrence rates and non-compliance with conventional treatments. In this sense, the aim of this single-arm, multicentre, prospective pilot study is to examine the safety, acceptability and clinical efficacy of a novel Virtual Reality-based system designed to provide binocular vision training to 7-15 year old amblyopic children complementing the concepts of perceptual learning and dichoptic training with a gamification approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Active vision therapy sessions with the NEIVATECH Virtual Reality-based system | The active visual therapy sessions with the NEIVATECH Virtual Reality-based system will be 18 in total, will have an average duration of half an hour and will be distributed over a month as follows: 5 sessions in the first two weeks after enrollment (Monday to Friday) and 4 sessions in the next two weeks (Monday to Thursday). |
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2024-07-01
- Completion
- 2024-09-30
- First posted
- 2021-03-29
- Last updated
- 2024-10-04
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04819386. Inclusion in this directory is not an endorsement.